20020023.TNBC
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.440
- UNFOLDED_PROTEIN_RESPONSE+0.350
- MYC_TARGETS_V1+0.280
- TGF_BETA_SIGNALING+0.280
- ANGIOGENESIS+0.250
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.170
- PROTEIN_SECRETION+0.150
- WNT_BETA_CATENIN_SIGNALING+0.130
- HYPOXIA+0.100
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.100
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.530
- INTERFERON_GAMMA_RESPONSE-0.400
- ESTROGEN_RESPONSE_EARLY-0.320
- INFLAMMATORY_RESPONSE-0.310
- APOPTOSIS-0.300
- CHOLESTEROL_HOMEOSTASIS-0.260
- APICAL_SURFACE-0.230
- P53_PATHWAY-0.230
- ESTROGEN_RESPONSE_LATE-0.220
- COMPLEMENT-0.210
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-XF-A9T0-01A-11R-A39I-07 | — | — | 0.780 |
| 2 | 59c50e1e-fc77-441e-93c2-f69c013f362c | — | — | 0.748 |
| 3 | SRR10900568 | — | — | 0.740 |
| 4 | C3N-03076 | — | cohortMD1 | 0.739 |
| 5 | 350f38a2-e597-494a-a387-975814453726 | — | — | 0.734 |
| 6 | 25f272b8-11f5-4edc-9c54-f4115fc0a5de | — | — | 0.733 |
| 7 | a7e776a3-4159-4cf7-8e05-2c2202330f58 | — | — | 0.733 |
| 8 | SRR11296878 | — | — | 0.732 |
| 9 | b1802901-fe29-4665-b960-ca263cba9243 | — | — | 0.722 |
| 10 | 20120131.TNBC | — | E | 0.719 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.440 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.350 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.280 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.280 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.250 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.170 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.150 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.130 | Inavolisib | — uncovered |
| HYPOXIA | 0.100 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.100 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.070 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.070 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.060 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.060 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.050 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.040 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.030 | Inavolisib | — uncovered |